H
Hiroshi Miyake
Researcher at Takeda Pharmaceutical Company
Publications - 15
Citations - 416
Hiroshi Miyake is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Virus & T cell. The author has an hindex of 9, co-authored 15 publications receiving 392 citations. Previous affiliations of Hiroshi Miyake include Kagoshima University.
Papers
More filters
Journal ArticleDOI
TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans
Masanori Baba,Katsunori Takashima,Hiroshi Miyake,Hiroshi Miyake,Naoyuki Kanzaki,Koichiro Teshima,Xin Wang,Mitsuru Shiraishi,Yuji Iizawa +8 more
TL;DR: TAK-652 is a promising candidate as a novel entry inhibitor of HIV-1 and displays favorable pharmacokinetics, and its plasma concentration was 7.2 ng/ml even 24 h after the administration of 25 mg.
Journal ArticleDOI
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
TL;DR: Several amino acid changes seemed to be required for R5 HIV-1 to acquire complete resistance to TAK-652, a novel small-molecule chemokine receptor antagonist of CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1) replication in vitro.
Journal ArticleDOI
Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist
Katsunori Takashima,Hiroshi Miyake,Hiroshi Miyake,Naoyuki Kanzaki,Yoshihiko Tagawa,Xin Wang,Yoshihiro Sugihara,Yuji Iizawa,Masanori Baba +8 more
TL;DR: The results suggest that TAK-220 selectively inhibits R5 HIV-1 replication by interfering with coreceptor-mediated entry of the virus into host cells, suggesting it is a promising candidate for the treatment of HIV- 1 infection.
Journal ArticleDOI
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Betty Lam,Yasuyoshi Arikawa,Joshua Cramlett,Qing Dong,Ron de Jong,Victoria A. Feher,Charles E. Grimshaw,Pamela Farrell,Isaac Hoffman,Andrew John Jennings,Jones Benjamin,Jennifer Matuszkiewicz,Joanne Miura,Hiroshi Miyake,Srinivasa Reddy Natala,Lihong Shi,Takahashi Masashi,Ewan Taylor,Corey Wyrick,Jason Yano,Jonathan Zalevsky,Zhe Nie +21 more
TL;DR: TAK-659 is currently undergoing Phase I clinical trials for advanced solid tumor and lymphoma malignancies, a Phase Ib study in advanced solid tumors in combination with nivolumab, and PhIb/II trials for relapsed/refractory AML.
Journal ArticleDOI
Establishment of a CCR5-Expressing T-Lymphoblastoid Cell Line Highly Susceptible to R5 HIV Type 1
TL;DR: Results indicate that the established T cell line MOLT-4/CCR5 cells will be an extremely useful tool for experiments with R5 HIV-1, and TAK-779, a novel small-molecule nonpeptide CCR5 antagonist, displayed potent antiviral activity, as demonstrated in peripheral blood mononuclear cells.